Temozolomide
- Generic Name
- Temozolomide
- Brand Names
- Temodar, Temomedac, Temodal, Temozolomide Sun, Temozolomide Accord, Temozolomide Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C6H6N6O2
- CAS Number
- 85622-93-1
- Unique Ingredient Identifier
- YF1K15M17Y
- Background
Refractory anaplastic astrocytoma (WHO grade III) and Glioblastoma multiforme (WHO grade IV) are primary malignant brain tumours with poor prognosis and limited treatment options. Despite considerable genetic heterogeneity, these tumours often have impaired DNA repair systems, rendering them initially sensitive to alkylating agents, although they invariably ...
- Indication
Temozolomide is indicated in adult patients for the treatment of newly diagnosed glioblastoma concomitantly with radiotherapy and for use as maintenance treatment thereafter. It is also indicated for the treatment of refractory anaplastic astrocytoma in adult patients or adjuvant therapy for adults with newly diagnosed anaplastic astrocytoma.
- Associated Conditions
- Advanced Melanoma, High Grade Glioma: Glioblastoma (GBM), Primary Central Nervous System Lymphoma, Refractory Ewing Sarcoma, Refractory Neuroblastoma, Soft Tissue Sarcoma, Advanced Neuroendocrine tumor, Newly diagnosed Anaplastic Astrocytoma (AA), Refractory Anaplastic astrocytoma, Refractory, advanced Mycosis fungoides, Refractory, advanced Sezary Syndrome
- Associated Therapies
- -
Temozolomide in Treating Patients With Metastatic Germ Cell Tumors That Have Not Responded to Cisplatin
- Conditions
- First Posted Date
- 2004-04-02
- Last Posted Date
- 2013-06-05
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00006043
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Temozolomide in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-small Cell Lung Cancer
- First Posted Date
- 2004-03-16
- Last Posted Date
- 2014-05-06
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 51
- Registration Number
- NCT00005037
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Waukesha Memorial Hospital, Waukesha, Wisconsin, United States
Temozolomide in Treating Patients With Anaplastic Oligodendroglioma
- Conditions
- First Posted Date
- 2004-03-12
- Last Posted Date
- 2013-06-20
- Lead Sponsor
- Duke University
- Target Recruit Count
- 60
- Registration Number
- NCT00003465
- Locations
- 🇺🇸
Duke Comprehensive Cancer Center, Durham, North Carolina, United States
Temozolomide in Patients With Progressive or Recurrent Non-small Cell Lung Cancer
- Conditions
- First Posted Date
- 2004-02-16
- Last Posted Date
- 2012-07-02
- Target Recruit Count
- 70
- Registration Number
- NCT00003062
- Locations
- 🇵🇱
Medical University of Gdansk, Gdansk, Poland
🇳🇱Vrije Universiteit Medisch Centrum, Amsterdam, Netherlands
🇮🇹Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors
- Conditions
- Previously Treated Childhood RhabdomyosarcomaRecurrent Childhood Brain TumorRecurrent Childhood Cerebellar AstrocytomaRecurrent Childhood Cerebral AstrocytomaRecurrent Childhood EpendymomaRecurrent Childhood Malignant Germ Cell TumorRecurrent Childhood MedulloblastomaRecurrent Childhood RhabdomyosarcomaRecurrent Childhood Soft Tissue SarcomaRecurrent Childhood Supratentorial Primitive Neuroectodermal Tumor
- Interventions
- First Posted Date
- 2004-02-12
- Last Posted Date
- 2013-06-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 95
- Registration Number
- NCT00077454
- Locations
- 🇺🇸
COG Phase I Consortium, Arcadia, California, United States
Carboplatin, Vincristine, and Temozolomide in Treating Children With Progressive and/or Symptomatic Low-Grade Glioma
- Conditions
- Interventions
- First Posted Date
- 2004-02-11
- Last Posted Date
- 2018-05-16
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 66
- Registration Number
- NCT00077207
- Locations
- 🇺🇸
Childrens Oncology Group, Philadelphia, Pennsylvania, United States
Temozolomide for Treatment of Brain Metastases From Non-Small Cell Lung Cancer (Study P03247)
- Conditions
- First Posted Date
- 2004-02-06
- Last Posted Date
- 2017-05-09
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 95
- Registration Number
- NCT00076856
Combination Chemotherapy in Treating Patients With Recurrent Glioblastoma Multiforme
- Conditions
- First Posted Date
- 2004-02-04
- Last Posted Date
- 2013-12-04
- Lead Sponsor
- Atlantic Health System
- Registration Number
- NCT00014105
- Locations
- 🇺🇸
Overlook Hospital, Summit, New Jersey, United States
Temozolomide Plus Carboplatin in Treating Patients With Recurrent Glioblastoma Multiforme
- Conditions
- First Posted Date
- 2004-01-14
- Last Posted Date
- 2013-07-11
- Lead Sponsor
- Fox Chase Cancer Center
- Registration Number
- NCT00021307
Temozolomide in Treating Patients With Solid Tumors That Have Spread to the Brain
- First Posted Date
- 2004-01-01
- Last Posted Date
- 2020-08-03
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 4
- Registration Number
- NCT00012116
- Locations
- 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.